Details

Summary: NACI update on the recommended use of palivizumab to reduce complications of respiratory syncytial virus infection in infants, CCDR 48(7/8) - Canada.ca

Metadata and links for an archived snapshot.

Source: Health Canada
Date: Apr 18, 2025 · edition #1
Timestamp: 2025-04-18T19:08:03.327Z
Language: en
Original URL: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-7-8-july-august-2022/summary-national-advisory-committee-immunization-naci-statement-update-recommended-use-palivizumab-reduce-complications-respiratory-syncytial-virus-infection-infants.html?wbdisable=false
Replay URL: https://replay.healtharchive.ca/job-1/20250418190803/https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-7-8-july-august-2022/summary-national-advisory-committee-immunization-naci-statement-update-recommended-use-palivizumab-reduce-complications-respiratory-syncytial-virus-infection-infants.html?wbdisable=false#ha_snapshot=231224
ID: 231224
Status: 200
Type: text/html

Independent archive · Not an official government website. For up-to-date recommendations, always consult the official source website.

Other snapshots